Study: Dalbavancin similar to standard treatment for staph bacteremia

Key takeaways:

Dalbavancin requires two doses 7 days apart, compared with standard 4- to 8-week therapy for S. aureus bacteremia.

The newer treatment was noninferior — but not superior — to standard treatment.

A randomized clinical trial set up to assess if dalbavancin is superior to standard treatment for Staphylococcus aureus bloodstream infections found that it was not, based on a set of five outcomes.

Dalbavancin, a long-acting lipoglycopeptide, was administered to participants in one arm of the trial in two IV doses given 7 days apart. Researchers tested that regimen against a standard 4- to 8-week regimen of antibiotics using the desirability of outcome ranking (DOOR) as a primary outcome.

A two-dose IV antibiotic treatment for S. aureus bloodstream infections is as effect